Загрузка...
Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment
INTRODUCTION: Type 2 diabetes (T2D) is the leading cause of chronic kidney disease (CKD). The recommended dose of the dipeptidyl peptidase-4 inhibitor saxagliptin is 2.5 mg in patients with moderate or severe renal impairment (creatinine clearance ≤50 mL/min). In this post hoc analysis, we assessed...
Сохранить в:
| Опубликовано в: : | Diabetes Ther |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Healthcare
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5014790/ https://ncbi.nlm.nih.gov/pubmed/27402391 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-016-0184-9 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|